X

Trial Profile

New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Florbetaben F18 (Primary) ; Florbetapir F 18 (Primary) ; Flutemetamol-F-18 (Primary)
Indications Alzheimer's disease
Focus Diagnostic use
Acronyms New IDEAS

Most Recent Events

21 Dec 2020 New trial record
14 Dec 2020 According to an Eli Lilly and Company media release, the study is directed by the Alzheimer's Association, managed by ACR and advised by CMS.
14 Dec 2020 According to an Eli Lilly and Company media release, the study protocol for New IDEAS was approved by CMS in April 2020 and is currently one of the only ways eligible patients may obtain a Medicare-reimbursed amyloid PET scan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com